Andere talen Bristol-Myers Squibb Company

Aandelen

BMY

US1101221083

Farmaceutische producten

Beurs gesloten - Nyse Andere beurzen 22:00:02 11-10-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
52,20 ^USD	-0,38%		-3,26%	+1,73%

09/10	BRISTOL-MYERS SQUIBB COMPANY : UBS herhaalt Neutraal advies	ZM
08/10	CytoDyn benoemt Max Lataillade tot Senior Vice President en Hoofd Klinische Ontwikkeling	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Sandoz commercialise l'anticancéreux paclitaxel aux Etats-Unis	11/10
CytoDyn Appoints Max Lataillade as Senior Vice President and Head of Clinical Development	08/10
Inozyme Pharma, Inc. Announces Appointment of Erik Harris to its Board of Directors	07/10
Bristol Myers : une approbation dans le cancer du poumon	04/10
Bristol-Myers Squibb Says FDA Approves Perioperative Treatment of Neoadjuvant Opdivo in NSCLC	04/10
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)	03/10
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer	03/10
Bristol-Myers Squibb's Opdivo Gets FDA Approval As Treatment for Resectable Non-Small Cell Lung Cancer	03/10
Wall Street clôture en hausse, records pour S&P 500 et Dow Jones	30/09
Sector Update: Health Care Stocks Advance Late Afternoon	30/09
US Judge Dismisses $6.4 Billion Suit Against Bristol Myers Over Delay in Drug Approvals	30/09
US Federal Judge Dismisses $6.4 Billion Suit Against Bristol Myers Squibb	30/09
Wall Street en ordre dispersé, le marché ralentit au dernier jour du trimestre	30/09
Sector Update: Health Care Stocks Steady Premarket Monday	30/09
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Ahead of Powell's Speech on Economic Outlook	30/09
Traders Consolidate Positions in Final Session for Q3, Driving Cautious Losses for US Equity Futures	30/09
Sector Update: Health Care	30/09
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting	30/09
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults	30/09
Top Premarket Gainers	30/09

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Bristol-Myers CEO zegt dat het bedrijf in overgang is

09 januari 2024 om 19:06 uur